In order to identify ruxolitinib mediated rebound activation of STAT5 target genes induction in MPN patients, we collected RNA-seq data of MPN patients treated with either ruxolitinib or other treatments (non-JAK inhibitor) from the MLL (Münchner Leukämielabor GmbH). The gene discussed is KMT2A; the disease is myeloproliferative disorder.